Literature DB >> 22156580

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.

Kristian Tveten1, Øystein L Holla, Jamie Cameron, Thea Bismo Strøm, Knut Erik Berge, Jon K Laerdahl, Trond P Leren.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the epidermal growth factor homology domain repeat A of the low-density lipoprotein receptor (LDLR) at the cell surface and disrupts recycling of the internalized LDLR. As a consequence, the LDLR is rerouted to the lysosomes for degradation. Although PCSK9 may bind to an LDLR lacking the ligand-binding domain, at least three ligand-binding repeats of the ligand-binding domain are required for PCSK9 to reroute the LDLR to the lysosomes. In this study, we have studied the binding of PCSK9 to an LDLR with or without the ligand-binding domain at increasingly acidic conditions in order to mimic the milieu of the LDLR:PCSK9 complex as it translocates from the cell membrane to the sorting endosomes. These studies have shown that PCSK9 is rapidly released from an LDLR lacking the ligand-binding domain at pH in the range of 6.9-6.1. A similar pattern of release at acidic pH was also observed for the binding to the normal LDLR of mutant PCSK9 lacking the C-terminal domain. Together these data indicate that an interaction between the negatively charged ligand-binding domain of the LDLR and the positively charged C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDLR during the early phase of endosomal acidification as the LDLR translocates from the cell membrane to the sorting endosome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156580     DOI: 10.1093/hmg/ddr578

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

1.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

Review 2.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

3.  A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function.

Authors:  Feng Gao; Hansel E Ihn; Marisa W Medina; Ronald M Krauss
Journal:  Hum Mol Genet       Date:  2013-01-07       Impact factor: 6.150

4.  Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions.

Authors:  Shengjun Wang; Yang Mao; Yoshiki Narimatsu; Zilu Ye; Weihua Tian; Christoffer K Goth; Erandi Lira-Navarrete; Nis B Pedersen; Asier Benito-Vicente; Cesar Martin; Kepa B Uribe; Ramon Hurtado-Guerrero; Christina Christoffersen; Nabil G Seidah; Rikke Nielsen; Erik I Christensen; Lars Hansen; Eric P Bennett; Sergey Y Vakhrushev; Katrine T Schjoldager; Henrik Clausen
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

5.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

6.  Small Molecule Inhibitors of the PCSK9·LDLR Interaction.

Authors:  Jaru Taechalertpaisarn; Bosheng Zhao; Xiaowen Liang; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2018-02-26       Impact factor: 15.419

Review 7.  Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Authors:  Evan A Stein; Gary D Swergold
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

8.  Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.

Authors:  Hong-mei Gu; Ayinuer Adijiang; Matthew Mah; Da-wei Zhang
Journal:  J Lipid Res       Date:  2013-10-08       Impact factor: 5.922

9.  PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

Authors:  Kristian Tveten; Thea Bismo Str M; Knut Erik Berge; Trond P Leren
Journal:  J Lipid Res       Date:  2013-03-18       Impact factor: 5.922

10.  Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.

Authors:  Yingnan Zhang; Charles Eigenbrot; Lijuan Zhou; Steven Shia; Wei Li; Clifford Quan; Jeffrey Tom; Paul Moran; Paola Di Lello; Nicholas J Skelton; Monica Kong-Beltran; Andrew Peterson; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2013-11-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.